Because anti-TNF therapy increases the risk of active TB development through the reactivation of latent TB [15, 16], guidelines recommend diagnosing and treating latent tuberculosis infection (LTBI) before starting anti-TNF therapy [12, 16, 17]. The gene discussed is TNF; the disease is tuberculosis.